{‘She possesses little experience’: this US healthcare field prepares for Høeg's role at the FDA.

Given that the United States proceeds with sweeping changes to its vaccine recommendations, one figure has emerged in a surprising turn: Høeg, a Danish American physician and epidemiologist who rose to prominence by casting doubt on coronavirus shots in the pandemic and has zeroed in on possible fatalities following COVID-19 immunization in her short time at the FDA.

Planned Changes to Pediatric Vaccine Program

Agency leaders had intended to announce sweeping changes to the childhood vaccination calendar recently, synchronizing the US with the Danish vaccine program, according to reports – a major change that would place the US at odds with much of the global community with no evidence for public health gain. The announcement has been delayed until the next year.

Instead of the top vaccines chief, Høeg is listed to address the audience at the gathering. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the office this year.

Consolidating Power at the Agency

Høeg's temporary position might represent a closer partnership between the drug and biologics branches as Høeg and Dr. Prasad strengthen their influence at the FDA – and it points to a renewed priority upon rolling back long-standing immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing certain pediatric immunization guidelines in the US in order to be more in line with the Danish model, a society with universal health coverage and a population about the population of the state of Wisconsin.

To date public appearances, she has continued to focus on vaccines – usually the domain of Dr. Prasad, head of the FDA’s vaccine center – as opposed to medication approval.

Questions Over Expertise

Høeg has no obvious track record in pharmaceutical research, regulation or leadership, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the agency head and CBER since March.

“She doesn’t seem to have the requisite experience” for leading the drug-regulation department, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She has no expertise in running a sizeable institution. She is not an expert in drug approvals.”

Past commissioners of the center would “grasp regulatory frameworks and the research of medication creation”, commented Dr. Janet Woodcock. “Clearly, she has not acquired the kind of background that prior appointees who ran the center have had.”

The drug center has an enormous workload at the FDA, Woodcock emphasized.

“Everybody just pays attention on the new drug program, but the generic program authorizes a multitude of generic drugs. There is also a biologic copycat branch, over-the-counter program and other areas, and every single one must be supervised,” Woodcock said. “The area you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Furthermore, a substantial management component to the role, which manages in excess of 5,000 personnel. “It’s a huge management job, if you execute it properly,” Woodcock said.

Response and Contentious Initiatives

When asked about concerns about Høeg’s credentials and whether this assignment signifies greater collaboration among agency officials on vaccines, a spokesperson responded that the “concerns are based on incorrect assumptions”.

“Her experience matches the responsibilities of her job,” the representative stated, citing the period Høeg spent guiding the agency head on “drug safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s new priority voucher program, a disputed one-day therapy clearance system that reportedly concerned her predecessors. “By what process are these drugs being selected for this expedited pathway? Who takes the calls?” Howard said. “There is a lot of confidentiality happening at the regulatory body right now.”

In general, he stated, “the Food and Drug Administration looks to be trending towards less stringent regulations of pharmaceuticals, aside from immunizations.”

Established Track Record on Vaccines

Regarding immunizations, Dr. Høeg has a clearer, if troubling, past, critics said. She released a research paper using unverified public submissions to estimate the frequency of myocarditis after Covid immunization. She consulted for the Florida top health official Dr. Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccinations are more dangerous than they are.

Included in her “policy goals” for the current federal leadership encompassed changing guidelines for novel immunizations and halting “non-essential” immunizations, she remarked post-election on a online show. At the FDA, Dr. Høeg has allegedly floated the idea of preventing adolescent males from obtaining COVID-19 vaccines.

“She’s an all-around ideologue who begins with her conclusions and tailors the evidence to accommodate the data in a highly misleading, untruthful manner,” Dr. Howard stated.

Gaining Influence and a “Push for Payback”

Høeg aligned with fellow skeptics, {like|